Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2010, Article ID 543704, 7 pages
http://dx.doi.org/10.1155/2010/543704
Review Article

Scleroderma Renal Crisis: A Pathology Perspective

1Department of Pathology, University of Pittsburgh Medical Center, A614 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15213, USA
2Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, 3500 Terrace Street, BST, S7, Pittsburgh, PA 15261, USA

Received 14 May 2010; Accepted 28 June 2010

Academic Editor: Lorinda Chung

Copyright © 2010 Ibrahim Batal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. I. Sakkas, “New developments in the pathogenesis of systemic sclerosis,” Autoimmunity, vol. 38, no. 2, pp. 113–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Sugimoto, M. Sanada, and A. Kashiwagi, “Is scleroderma renal crisis with anti-centromere antibody-positive limited cutaneous systemic sclerosis overlooked in patients with hypertension and/or renal dysfunction?” Nephrology, vol. 13, no. 2, pp. 179–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Sugimoto, M. Soumura, K. Danno et al., “Scleroderma renal crisis in a patient with anticentromere antibody-positive limited cutaneous systemic sclerosis,” Modern Rheumatology, vol. 16, no. 5, pp. 309–311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. E. A. Gonzalez, E. Schmulbach, and B. Bastani, “Scleroderma renal crisis with minimal skin involvement and no serologic evidence of systemic sclerosis,” American Journal of Kidney Diseases, vol. 23, no. 2, pp. 317–319, 1994. View at Google Scholar · View at Scopus
  5. C. Chizzolini, “Update on pathophysiology of scleroderma with special reference to immunoinflammatory events,” Annals of Medicine, vol. 39, no. 1, pp. 42–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Sato, M. Fujimoto, M. Hasegawa, K. Takehara, and T. F. Tedder, “Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis,” Molecular Immunology, vol. 41, no. 12, pp. 1123–1133, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. I. Sakkas, I. C. Chikanza, and C. D. Platsoucas, “Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis,” Nature Clinical Practice Rheumatology, vol. 2, no. 12, pp. 679–685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Chang, R. J. Wang, D. T. Yangco, G. C. Sharp, G. R. Komatireddy, and R. W. Hoffman, “Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay,” Clinical Immunology and Immunopathology, vol. 89, no. 1, pp. 71–78, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Santiago, M. Baron, M. Hudson, R. W. Burlingame, and M. J. Fritzler, “Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA,” Journal of Rheumatology, vol. 34, no. 7, pp. 1528–1534, 2007. View at Google Scholar · View at Scopus
  10. M. Worda, R. Sgonc, H. Dietrich et al., “In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay,” Arthritis and Rheumatism, vol. 48, no. 9, pp. 2605–2614, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Mihai and J. W. C. Tervaert, “Anti-endothelial cell antibodies in systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 319–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kobayashi, T. Nishimaki, S. Kaise et al., “Immunohistological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis,” Clinical Rheumatology, vol. 18, no. 5, pp. 425–427, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Batal, R. T. Domsic, A. Shafer et al., “Renal biopsy findings predicting outcome in scleroderma renal crisis,” Human Pathology, vol. 40, no. 3, pp. 332–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. C. Trostle, C. D. Bedetti, V. D. Steen, M. R. Al-Sabbagh, B. Zee, and T. A. Medsger Jr., “Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 393–400, 1988. View at Google Scholar · View at Scopus
  15. D. J. Helfrich, B. Banner, V. D. Steen, and T. A. Medsger Jr., “Normotensive renal failure in systemic sclerosis,” Arthritis and Rheumatism, vol. 32, no. 9, pp. 1128–1134, 1989. View at Google Scholar · View at Scopus
  16. Y. S. Haviv and R. Safadi, “Normotensive scleroderma renal crisis: case report and review of the literature,” Renal Failure, vol. 20, no. 5, pp. 733–736, 1998. View at Google Scholar · View at Scopus
  17. B. Lewandowski, I. Domysławska, P. A. Klimiuk, and S. Sierakowski, “Kidney crisis in systemic sclerosis,” Roczniki Akademii Medycznej w Bialymstoku, vol. 50, pp. 294–296, 2005. View at Google Scholar · View at Scopus
  18. H. Penn, A. J. Howie, E. J. Kingdon et al., “Scleroderma renal crisis: patient characteristics and long-term outcomes,” QJM, vol. 100, no. 8, pp. 485–494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. P. Denton, G. Lapadula, L. Mouthon, and U. Müller-Ladner, “Renal complications and scleroderma renal crisis,” Rheumatology, vol. 48, pp. iii32–35, 2009. View at Google Scholar · View at Scopus
  20. V. D. Steen and T. A. Medsger Jr., “Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis,” Arthritis and Rheumatism, vol. 41, no. 9, pp. 1613–1619, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Sarwar, L. R. Espinoza, H. McGrath Jr., Z. Yaqub, and E. Cucurull, “Scleroderma renal crisis following widespread application of topical triamcinolone,” Journal of Clinical Rheumatology, vol. 10, no. 5, pp. 275–276, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. V. D. Steen, “Autoantibodies in systemic sclerosis,” Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 35–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. F. C. Arnett, J. D. Reveille, R. Goldstein et al., “Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis,” Arthritis and Rheumatism, vol. 39, no. 7, pp. 1151–1160, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Aggarwal, M. Lucas, N. Fertig, C. V. Oddis, and T. A. Medsger, “Anti-U3 RNP autoantibodies in systemic sclerosis,” Arthritis and Rheumatism, vol. 60, no. 4, pp. 1112–1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. V. D. Steen and T. A. Medsger Jr., “Long-term outcomes of scleroderma renal crisis,” Annals of Internal Medicine, vol. 133, no. 8, pp. 600–603, 2000. View at Google Scholar · View at Scopus
  26. E. R. Fisher and G. P. Rodnan, “Pathologic observations concerning the kidney in progressive systemic sclerosis,” A. M. A. Archives of Pathology, vol. 65, no. 1, pp. 29–39, 1958. View at Google Scholar
  27. L. Mouthon, A. Bérezné, G. Bussone, L.-H. Noël, P. M. Villiger, and L. Guillevin, “Scleroderma renal crisis: a rare but severe complication of systemic sclerosis,” Clinical Reviews in Allergy and Immunology. In press. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Tostivint, B. Mougenot, A. Flahault et al., “Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade,” Nephrology Dialysis Transplantation, vol. 17, no. 7, pp. 1228–1234, 2002. View at Google Scholar · View at Scopus
  29. D. Lapenas, G. P. Rodnan, and T. Cavallo, “Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma),” American Journal of Pathology, vol. 91, no. 2, pp. 243–258, 1978. View at Google Scholar · View at Scopus
  30. R. C. McCoy, C. C. Tisher, P. F. Pepe, and L. A. Cleveland, “The kidney in progressive systemic sclerosis. Immunohistochemical and antibody elution studies,” Laboratory Investigation, vol. 35, no. 2, pp. 124–131, 1976. View at Google Scholar · View at Scopus
  31. A. R. McGiven, W. G. De Boer, and A. J. Barnett, “Renal immune deposits in scleroderma,” Pathology, vol. 3, no. 2, pp. 145–150, 1971. View at Google Scholar · View at Scopus
  32. F. G. Silva and C. L. Pirani, “Electron microscopic study of medical diseases of the kidney: update—1988,” Modern Pathology, vol. 1, no. 4, pp. 292–315, 1988. View at Google Scholar · View at Scopus
  33. R. A. Sinclair, T. T. Antonovych, and F. K. Mostofi, “Renal proliferative arteriopathies and associated glomerular changes. A light and electron microscopic study,” Human Pathology, vol. 7, no. 5, pp. 565–588, 1976. View at Google Scholar · View at Scopus
  34. M. I. Salomon, J. Lamovec, and V. Tcherkoff, “Renal lesions in scleroderma,” Angiology, vol. 29, no. 8, pp. 569–578, 1978. View at Google Scholar · View at Scopus
  35. R. B. Colvin, “Antibody-mediated renal allograft rejection: diagnosis and pathogenesis,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1046–1056, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. H. E. Feucht, H. Schneeberger, G. Hillebrand et al., “Capillary deposition of C4d complement fragment and early renal graft loss,” Kidney International, vol. 43, no. 6, pp. 1333–1338, 1993. View at Google Scholar · View at Scopus
  37. I. Batal, A. Girnita, A. Zeevi et al., “Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney,” Modern Pathology, vol. 21, no. 12, pp. 1490–1498, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Sis and P. F. Halloran, “Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection,” Current Opinion in Organ Transplantation, vol. 15, no. 1, pp. 42–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Ramaswami, T. Kandaswamy, T. Rajendran et al., “Scleroderma with crescentic glomerulonephritis: a case report,” Journal of Medical Case Reports, vol. 2, article 151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Endo, T. Hosono, and H. Kondo, “Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis,” Journal of Rheumatology, vol. 21, no. 5, pp. 864–870, 1994. View at Google Scholar · View at Scopus
  41. D. L. Kamen, F. M. Wigley, and A. N. Brown, “Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma—a different kind of renal crisis,” Journal of Rheumatology, vol. 33, no. 9, pp. 1886–1888, 2006. View at Google Scholar · View at Scopus
  42. T. Namba, M. Hatanaka, A. Takahashi et al., “A case of scleroderma with rapid progressive glomerulonephritis associated with both MPO-ANCA and anti-GBM antibodies,” Nippon Jinzo Gakkai Shi, vol. 50, no. 1, pp. 64–68, 2008. View at Google Scholar · View at Scopus
  43. M. Kirschstein, U. Helmchen, R. Jensen, R. M. Küster, and H. Lehmann, “Kidney involvement in a 17-year-old boy with eosinophilic fasciitis,” Clinical Nephrology, vol. 52, no. 3, pp. 183–187, 1999. View at Google Scholar · View at Scopus
  44. R. A. Stone, C. C. Tisher, H. K. Hawkins, and R. R. Robinson, “Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated by acute renal failure,” American Journal of Medicine, vol. 56, no. 1, pp. 119–123, 1974. View at Google Scholar · View at Scopus
  45. P. J. Cannon, M. Hassar, D. B. Case, W. J. Casarella, S. C. Sommers, and E. C. LeRoy, “The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation,” Medicine, vol. 53, no. 1, pp. 1–46, 1974. View at Google Scholar · View at Scopus
  46. V. Steen, C. P. Denton, J. E. Pope, and M. Matucci-Cerinic, “Digital ulcers: overt vascular disease in systemic sclerosis,” Rheumatology, vol. 48, pp. iii19–24, 2009. View at Google Scholar · View at Scopus
  47. V. D. Steen, “Renal involvement in systemic sclerosis,” Clinics in Dermatology, vol. 12, no. 2, pp. 253–258, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Penn, A. J. Howie, R. J. Stratton et al., “The prognostic value of renal biopsy in scleroderma renal crisis,” Arhtritis and Rheumatism, vol. 56, pp. 53–54, 2007, abstract #3. View at Google Scholar
  49. M. G. Hunter, S. Hurwitz, C. O. C. Bellamy, and J. S. Duffield, “Quantitative morphometry of lupus nephritis: the significance of collagen, tubular space, and inflammatory infiltrate,” Kidney International, vol. 67, no. 1, pp. 94–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. D. A. Collins, S. Patel, J. B. Eastwood, and B. E. Bourke, “Favourable outcome of scleroderma renal crisis,” Journal of the Royal Society of Medicine, vol. 89, no. 1, pp. 49–50, 1996. View at Google Scholar · View at Scopus
  51. V. D. Steen, J. P. Costantino, A. P. Shapiro, and T. A. Medsger Jr., “Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors,” Annals of Internal Medicine, vol. 113, no. 5, pp. 352–357, 1990. View at Google Scholar · View at Scopus
  52. E. Y. Rhew and W. G. Barr, “Scleroderma renal crisis: new insights and developments,” Current Rheumatology Reports, vol. 6, no. 2, pp. 129–136, 2004. View at Google Scholar · View at Scopus
  53. E. C. LeRoy and R. M. Fleischmann, “The management of renal scleroderma. Experience with dialysis, nephrectomy and transplantation,” American Journal of Medicine, vol. 64, no. 6, pp. 974–978, 1978. View at Google Scholar · View at Scopus
  54. A. J. Bleyer, L. A. Donaldson, M. McIntosh, and P. L. Adams, “Relationship between underlying renal disease and renal transplantation outcome,” American Journal of Kidney Diseases, vol. 37, no. 6, pp. 1152–1161, 2001. View at Google Scholar · View at Scopus
  55. A. R. Nissenson and F. K. Port, “Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders,” Quarterly Journal of Medicine, vol. 74, no. 273, pp. 63–74, 1990. View at Google Scholar · View at Scopus
  56. I. Batal, S. Bastacky, and P. Randhawa, “The outcome of kidney transplantation in patients with scleroderma,” American Journal of Transplantation, vol. 7, no. 2, pp. 363–363, 2007, abstract 835. View at Google Scholar
  57. R. Shapiro, M. L. Jordan, V. P. Scantlebury et al., “A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients,” Transplantation Proceedings, vol. 27, no. 1, pp. 814–817, 1995. View at Google Scholar · View at Scopus
  58. W. Y. Cheung, I. W. Gibson, D. Rush, J. Jeffery, and M. Karpinski, “Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade,” American Journal of Kidney Diseases, vol. 45, no. 5, pp. 930–934, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. P.-T. T. Pham, P.-C. T. Pham, G. M. Danovitch et al., “Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature,” American Journal of Transplantation, vol. 5, no. 10, pp. 2565–2569, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Liptak and B. Ivanyi, “Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts,” Nature Clinical Practice Nephrology, vol. 2, no. 7, pp. 398–404, 2006. View at Publisher · View at Google Scholar · View at Scopus